The majority of clinical trials approved for CAR-NK cells are focused on hematologic malignancies rather than metastatic solid tumors, with only one trial currently evaluating the response of castration-resistant prostate cancer patients to CAR-NK cells targeting Prostate-Specific Membrane Antigen (PSMA) [95]. This evidence concerns the gene FOLH1 and prostate cancer.